Zurich Cantonal Bank’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.98M | Buy |
115,775
+4,081
| +4% | +$83.9K | 0.01% | 925 |
|
|
2026
Q1 | $2.14M | Buy |
111,694
+64,235
| +135% | +$1.28M | ﹤0.01% | 1010 |
|
|
2025
Q4 | $784K | Hold |
47,459
| – | – | ﹤0.01% | 1495 |
|
|
2025
Q3 | $689K | Buy |
47,459
+3,872
| +9% | +$55.6K | ﹤0.01% | 1532 |
|
|
2025
Q2 | $610K | Buy |
43,587
+3,830
| +10% | +$53.9K | ﹤0.01% | 1533 |
|
|
2025
Q1 | $540K | Hold |
39,757
| – | – | ﹤0.01% | 1556 |
|
|
2024
Q4 | $810K | Buy |
39,757
+10,038
| +34% | +$257K | ﹤0.01% | 1322 |
|
|
2024
Q3 | $866K | Buy |
29,719
+3,316
| +13% | +$82.2K | ﹤0.01% | 1201 |
|
|
2024
Q2 | $613K | Buy |
26,403
+1,372
| +5% | +$26.3K | ﹤0.01% | 1354 |
|
|
2024
Q1 | $514K | Buy |
25,031
+2,244
| +10% | +$42.2K | ﹤0.01% | 1446 |
|
|
2023
Q4 | $489K | Buy |
22,787
+2,108
| +10% | +$41.8K | ﹤0.01% | 1514 |
|
|
2023
Q3 | $427K | Buy |
20,679
+2,124
| +11% | +$53.9K | ﹤0.01% | 1492 |
|
|
2023
Q2 | $548K | Buy |
18,555
+1,737
| +10% | +$48.8K | ﹤0.01% | 1294 |
|
|
2023
Q1 | $387K | Buy |
16,818
+4,500
| +37% | +$124K | ﹤0.01% | 1445 |
|
|
2022
Q4 | $343K | Buy |
12,318
+810
| +7% | +$24.1K | ﹤0.01% | 1482 |
|
|
2022
Q3 | $353K | Hold |
11,508
| – | – | ﹤0.01% | 1406 |
|
|
2022
Q2 | $339K | Buy |
11,508
+118
| +1% | +$3.09K | ﹤0.01% | 1476 |
|
|
2022
Q1 | $366K | Buy |
11,390
+446
| +4% | +$15.3K | ﹤0.01% | 1529 |
|
|
2021
Q4 | $488K | Buy |
10,944
+2,118
| +24% | +$100K | ﹤0.01% | 1456 |
|
|
2021
Q3 | $445K | Sell |
8,826
-11
| -0.1% | -$620 | ﹤0.01% | 1377 |
|
|
2021
Q2 | $693K | Sell |
8,837
-446
| -5% | -$27.6K | ﹤0.01% | 1038 |
|
|
2021
Q1 | $530K | Buy |
9,283
+77
| +0.8% | +$5.16K | ﹤0.01% | 1185 |
|
|
2020
Q4 | $771K | Buy |
9,206
+632
| +7% | +$38.2K | ﹤0.01% | 1066 |
|
|
2020
Q3 | $307K | Hold |
8,574
| – | – | ﹤0.01% | 1325 |
|
|
2020
Q2 | $207K | Buy |
8,574
+2,386
| +39% | +$56.1K | ﹤0.01% | 1492 |
|
|
2020
Q1 | $108K | Buy |
6,188
+2,740
| +79% | +$57.2K | ﹤0.01% | 1565 |
|
|
2019
Q4 | $60K | Sell |
3,448
-1,541
| -31% | -$25.7K | ﹤0.01% | 2041 |
|
|
2019
Q3 | $76K | Hold |
4,989
| – | – | ﹤0.01% | 1762 |
|
|
2019
Q2 | $104K | Sell |
4,989
-4,759
| -49% | -$107K | ﹤0.01% | 1595 |
|
|
2019
Q1 | $226K | Sell |
9,748
-688
| -7% | -$14.4K | ﹤0.01% | 1140 |
|
|
2018
Q4 | $216K | Buy |
10,436
+1,237
| +13% | +$22.4K | ﹤0.01% | 1166 |
|
|
2018
Q3 | $200K | Buy |
9,199
+1,999
| +28% | +$33.1K | ﹤0.01% | 1304 |
|
|
2018
Q2 | $110K | Hold |
7,200
| – | – | ﹤0.01% | 1589 |
|
|
2018
Q1 | $142K | Buy |
+7,200
| New | +$148K | ﹤0.01% | 1404 |
|
Other funds holding DNLI
Zurich Cantonal Bank's DNLI Position: Q2 2026 in Review
Zurich Cantonal Bank increased its Denali Therapeutics (DNLI) stake by 3.7% in Q2 2026, buying an estimated $83.9K and bringing the position to 115,775 shares worth $2.98M. The position accounts for 0.01% of the portfolio, ranked #925.
Zurich Cantonal Bank first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Zurich Cantonal Bank held 115,775 shares of Denali Therapeutics worth $2.98M as of Q2 2026.
- Zurich Cantonal Bank bought 4,081 Denali Therapeutics shares in Q2 2026, an estimated $83.9K.
- Denali Therapeutics made up 0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #925 holding.
- Zurich Cantonal Bank first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.